Skip to main page content
Accesskeys
  1. Error occurred: The following PMID is not available: 27765908
  2. Clements D, Thomas J, Landi S, Plenderleith I, Benz C. Oral BCG sensitization . In: In "Neoplasm Immunity: Mechanisms" (Book). Chicago: ITR; 1976. p.135-144.
  3. Benz CC, Thomas JW, Mandl M, Morgan N. Acquired chronic candidiasis treated with transfer factor. Br J Dermatol. 1977 Jul;97(1):87-91. doi: 10.1111/j.1365-2133.1977.tb15433.x. PubMed PMID: 889704.
  4. Cadman E, Benz C. Uridine and cytidine metabolism following inhibition of de novo pyrimidine synthesis by pyrazofurin. Biochim Biophys Acta. 1980 Oct 17;609(3):372-82. doi: 10.1016/0005-2787(80)90111-2. PubMed PMID: 7437431.
  5. Benz C, Schoenberg M, Choti M, Cadman E. Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. J Clin Invest. 1980 Nov;66(5):1162-5. doi: 10.1172/JCI109946. PubMed PMID: 7430346; PubMed Central PMCID: PMC371555.
  6. Cadman E, Benz C, Heimer R, O'Shaughnessy J. The modulation of 5 fluorouracil metabolism by inhibitors of de novo purine synthesis . In: In "Nucleotides and Cancer Treatment" (Book). Sydney: Academic Press; 1981. p.242-251.
  7. Benz C, Cadman E. Biochemical alterations during unperturbed suspension growth of L1210 cells. Cancer Res. 1981 Jan;41(1):157-63. PubMed PMID: 6160904.
  8. Cadman E, Heimer R, Benz C. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem. 1981 Feb 25;256(4):1695-704. PubMed PMID: 6161926.
  9. Cadman E, Benz C, Heimer R, O'Shaughnessy J. Effect of de novo purine synthesis inhibitors on 5-fluorouracil metabolism and cytotoxicity. Biochem Pharmacol. 1981 Sep 1;30(17):2469-72. doi: 10.1016/0006-2952(81)90343-9. PubMed PMID: 21043247.
  10. Benz C, Tillis T, Tattelman E, Cadman E. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res. 1982 May;42(5):2081-6. PubMed PMID: 6175406.
  11. Cadman E, Benz C. Modulation of 5-fluorouracil toxicity via estrogen receptor . In: In "Biological and biochemical markers of neoplastic transformation" (Book). New York: Plenum Press; 1983. p.381-390.
  12. Cadman E, Grant S, Benz C. Biochemical modulation as a guide to rational approach for combination chemotherapy for the treatment of cancer . In: In "Adrenal and Endocrine Tumors in Children" (Book). Boston: Springer; 1983. p.101-122.
  13. Benz C, Silverberg M, Cadman E. Use of high-dose oral methotrexate sequenced at 24 hours with 5-FU: a clinical toxicity study. Cancer Treat Rep. 1983 Mar;67(3):297-9. PubMed PMID: 6831477.
  14. Benz C, Santos G, Cadman E. Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA. Cancer Res. 1983 Nov;43(11):5304-8. PubMed PMID: 6616465.
  15. Benz C, Cadman E, Gwin J, Wu T, Amara J, Eisenfeld A, Dannies P. Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro. Cancer Res. 1983 Nov;43(11):5298-303. PubMed PMID: 6616464.
  16. Benz C, Choti M, Newcomer L, Cadman E. Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma. Cancer Chemother Pharmacol. 1984;12(2):104-10. PubMed PMID: 6199130.
  17. Benz C, Wiznitzer I. Steroid binding and cytotoxicity in cultured human pancreatic carcinomas . In: I "Hormones and Cancer 2" (Book). Bresciani F, King R, Lippman M, Namer M, Raynaud J, editors. New York: Raven Press; 1984. p.223-228.
  18. Wilbur B, Benz C, DeGregorio M. Quantitation of tamoxifen, 4 hydroxytamoxifen, and N desmethyltamoxifen in human plasma by high-performance liquid chromatography. Analytical letters. 1985; 18:1915-1924.
  19. Degregorio M, Holleran W, Benz C, Cadman C. Quantitative analysis of 5 fluorouracil in human serum by high-performance liquid chromatography. Analytical letters. 1985; 18:51-55.
  20. Benz C, Wiznitzer I, Lee S. Flow cytometric analysis of fluorescent estrogen binding in cancer cell suspensions . In: In "Morphologic Localization of Putative Steroid Receptors, Vol. I: Experimental Systems" (Book). Lee S, Pertzchuk L, editors. Boca Raton, Florida: CRC Press, Inc.; 1985. p.95-110.
  21. Linker C, Benz C. Hematology and Oncology . In: In "Review of General Internal Medicine" (Book). Smith L, Wyngaarden J, editors. Philadelphia: W.B. Saunders Co.; 1985. p.125-144.
  22. Hait WN, Grais L, Benz C, Cadman EC. Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin. Cancer Chemother Pharmacol. 1985;14(3):202-5. PubMed PMID: 3995682.
  23. Benz C, Wiznitzer I, Lee SH. Flow cytometric analysis of fluorescein-conjugated estradiol (E-BSA-FITC) binding in breast cancer suspensions. Cytometry. 1985 May;6(3):260-7. doi: 10.1002/cyto.990060313. PubMed PMID: 3996141.
  24. Benz C, DeGregorio M, Saks S, Sambol N, Holleran W, Ignoffo R, Lewis B, Cadman E. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response. Cancer Res. 1985 Jul;45(7):3354-8. PubMed PMID: 4005858.
  25. Benz C. Measurement of ligand binding, E-BSA-FITC: Reply to Dr. Asherhoft. Cytometry. 1986; 7(299):1986.
  26. Benz C, Hollander C, Miller B. Hormones and cancer . In: In "Basic and Clinical Endocrinology" (Book). Greenspan F, Forsham P, editors. Los Altos, CA: Lange Medical Publications; 1986. p.624-635.
  27. Benz C, Heimer R, Cadman E. Modulation of 5-fluorouracil cytotoxicity by intracellular pools of 5-phosphoribosyl-1-pyrophosphate (PRPP) . In: In "Biochemical Modulation: Experimental and Clinical Approaches" (Book). Valeriote F, Baker L, editors. Boston: Martinus Nijhoff; 1986. p.93-105.
  28. Keniry M, Benz C, Shafer RH, James TL. Noninvasive spectroscopic analysis of fluoropyrimidine metabolism in cultured tumor cells. Cancer Res. 1986 Apr;46(4 Pt 1):1754-8. PubMed PMID: 3456267.
  29. Benz C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res. 1986 May;46(5):2276-81. PubMed PMID: 3697973.
  30. Benz C, Hollander C, Keniry M, James TL, Mitchell M. Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123. J Clin Invest. 1987 Feb;79(2):517-23. doi: 10.1172/JCI112842. PubMed PMID: 3805280; PubMed Central PMCID: PMC424116.
  31. Armstrong RD, Ward TJ, Pattabiraman N, Benz C, Armstrong DW. Separation of tamoxifen geometric isomers and metabolites by bonded-phase beta-cyclodextrin chromatography. J Chromatogr. 1987 Feb 20;414(1):192-6. doi: 10.1016/0378-4347(87)80040-3. PubMed PMID: 3571384.
  32. Benz C, Gandara D, Miller B, Drakes T, Monroe S, Wilbur B, DeGregorio M. Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity. Cancer Treat Rep. 1987 Mar;71(3):283-9. PubMed PMID: 3493069.
  33. Benz C, Santos GF. Effects of cis- and trans-tamoxifen isomers on RNA incorporation of human breast cancer cells. Mol Pharmacol. 1987 Jul;32(1):13-6. PubMed PMID: 3600613.
  34. Benz C, Keniry M, Goldberg H. Selective toxicity of gossypol against epithelial tumors and its detection by magnetic resonance spectroscopy. Contraception. 1988 Mar;37(3):221-8. PubMed PMID: 3370994.
  35. Santos GF, Scott GK, Lee WM, Liu E, Benz C. Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. J Biol Chem. 1988 Jul 15;263(20):9565-8. PubMed PMID: 3290209.
  36. Wiebe VJ, Benz CC, DeGregorio MW. Clinical pharmacokinetics of drugs used in the treatment of breast cancer. Clin Pharmacokinet. 1988 Sep;15(3):180-93. doi: 10.2165/00003088-198815030-00003. Review. PubMed PMID: 3052986.
  37. Liu E, Dollbaum C, Scott G, Rochlitz C, Benz C, Smith HS. Molecular lesions involved in the progression of a human breast cancer. Oncogene. 1988 Sep;3(3):323-7. PubMed PMID: 2849743.
  38. Rochlitz CF, Scott GK, Dodson JM, Benz CC. Use of the polymerase chain reaction technique to create base-specific ras oncogene mutations. DNA. 1988 Sep;7(7):515-9. PubMed PMID: 3061761.
  39. Rochlitz CF, Benz CC. Oncogenes in human solid tumors. Cancer Treat Res. 1989;47:199-240. Review. PubMed PMID: 2576998.
  40. Damon LE, Cadman E, Benz C. Enhancement of 5-fluorouracil antitumor effects by the prior administration of methotrexate. Pharmacol Ther. 1989;43(2):155-85. Review. PubMed PMID: 2675132.
  41. Rochlitz CF, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res. 1989 Jan 15;49(2):357-60. PubMed PMID: 2642738.
  42. Liu E, Santos G, Lee WM, Osborne CK, Benz CC. Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene. 1989 Aug;4(8):979-84. PubMed PMID: 2668848.
  43. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene. 1989 Sep;4(9):1153-7. PubMed PMID: 2780051.
  44. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol. 1989 Sep;7(9):1359-64. doi: 10.1200/JCO.1989.7.9.1359. PubMed PMID: 2527971.
  45. Keniry MA, Hollander C, Benz CC. The effect of gossypol and 6-aminonicotinamide on tumor cell metabolism: a 31P-magnetic resonance spectroscopic study. Biochem Biophys Res Commun. 1989 Oct 31;164(2):947-53. doi: 10.1016/0006-291x(89)91550-7. PubMed PMID: 2530981.
  46. Benz CC, Scott GK, Santos GF, Smith HS. Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. J Natl Cancer Inst. 1989 Nov 15;81(22):1704-9. doi: 10.1093/jnci/81.22.1704. PubMed PMID: 2572702.
  47. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol. 1990;25(4):247-51. PubMed PMID: 2136809.
  48. Johnston JD, Brand MD. The mechanism of Ca2+ stimulation of citrulline and N-acetylglutamate synthesis by mitochondria. Biochim Biophys Acta. 1990 Jan 29;1033(1):85-90. doi: 10.1016/0304-4165(90)90198-6. PubMed PMID: 2105747.
  49. Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol. 1990 Jun;37(6):840-7. PubMed PMID: 2193225.